Status:
TERMINATED
Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's Lymphoma
Lead Sponsor:
University of Cologne
Collaborating Sponsors:
German Hodgkin's Lymphoma Study Group
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Conditions:
Hodgkin Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The primary objective of this study is to evaluate wether bortezomib and dexamethasone are active in patients with relapsed Hodgkin's lymphoma.
Detailed Description
The proteasome-inhibitor bortezomib (Velcade) shows promising activity in various human lymphoma cell line. In addition, several studies in heavily pretreated patients with lymphoma showed also promis...
Eligibility Criteria
Inclusion
- Hodgkin's lymphoma
- Second or higher relapse (first relapse if high-dose chemotherapy not possible)
- Age \>/= 18 years
- No major organ dysfunction or intercurrent disorder
- Written informed consent
Exclusion
- Pregnant or nursing
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT00148018
Start Date
March 1 2005
Last Update
July 10 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Cologne
Cologne, North Rhine-Westphalia, Germany, 50924